Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
New York, NY
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Portland, OR
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Austin, TX
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
College Station, TX
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
College Station, TX
Click here to add this to my saved trials
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
San Antonio, TX
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Webster, TX
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated:  12/17/2015
mi
from
Kawaguchi Saitama,
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)
Status: Enrolling
Updated: 12/17/2015
mi
from
Kawaguchi Saitama,
Click here to add this to my saved trials
A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma
A Pilot Study Comparing the Efficacy of 1064 Q-switch Laser vs. Glycolic Acid Peels for the Treatment of Melasma: A Randomized Control Trial
Status: Enrolling
Updated:  12/28/2015
Northwestern University Department of Dermatology
mi
from
Chicago, IL
A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma
A Pilot Study Comparing the Efficacy of 1064 Q-switch Laser vs. Glycolic Acid Peels for the Treatment of Melasma: A Randomized Control Trial
Status: Enrolling
Updated: 12/28/2015
Northwestern University Department of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough
Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough
Status: Enrolling
Updated:  1/7/2016
Mayo Clinic Florida
mi
from
Jacksonville, FL
Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough
Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough
Status: Enrolling
Updated: 1/7/2016
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
Status: Enrolling
Updated:  1/11/2016
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
Status: Enrolling
Updated: 1/11/2016
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Click here to add this to my saved trials
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
Status: Enrolling
Updated:  1/11/2016
Wills Eye Hospital
mi
from
Philadelphia, PA
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
Status: Enrolling
Updated: 1/11/2016
Wills Eye Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
Status: Enrolling
Updated:  1/11/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions
Status: Enrolling
Updated: 1/11/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Androgenetic Alopecia in Fabry Disease
Androgenetic Alopecia in Fabry Disease
Status: Enrolling
Updated:  1/12/2016
Baylor University Medical Center
mi
from
Dallas, TX
Androgenetic Alopecia in Fabry Disease
Androgenetic Alopecia in Fabry Disease
Status: Enrolling
Updated: 1/12/2016
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
ADRN Influenza Vaccine Pilot
An Open Label Study in Adults With Atopic Dermatitis to Assess Variability in Immune Response to Fluzone® Intradermal Vaccine
Status: Enrolling
Updated:  1/12/2016
National Jewish Health
mi
from
Denver, CO
ADRN Influenza Vaccine Pilot
An Open Label Study in Adults With Atopic Dermatitis to Assess Variability in Immune Response to Fluzone® Intradermal Vaccine
Status: Enrolling
Updated: 1/12/2016
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated:  1/13/2016
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated: 1/13/2016
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated:  1/13/2016
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated: 1/13/2016
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated:  1/13/2016
Children's Hospital Oakland Research Institute
mi
from
Oakland, CA
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated: 1/13/2016
Children's Hospital Oakland Research Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated:  1/13/2016
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated: 1/13/2016
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated:  1/13/2016
Children's Hospital Oakland Research Institiute
mi
from
Oakland, CA
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome
Status: Enrolling
Updated: 1/13/2016
Children's Hospital Oakland Research Institiute
mi
from
Oakland, CA
Click here to add this to my saved trials
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
A Randomized, Phase II Multicenter Trial Evaluating the Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)
Status: Enrolling
Updated:  1/13/2016
Children's Hospital Oakland Research Institute
mi
from
Oakland, CA
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
A Randomized, Phase II Multicenter Trial Evaluating the Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)
Status: Enrolling
Updated: 1/13/2016
Children's Hospital Oakland Research Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
A Randomized, Phase II Multicenter Trial Evaluating the Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)
Status: Enrolling
Updated:  1/13/2016
Children's Hospital Oakland Research Institiute
mi
from
Oakland, CA
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
A Randomized, Phase II Multicenter Trial Evaluating the Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)
Status: Enrolling
Updated: 1/13/2016
Children's Hospital Oakland Research Institiute
mi
from
Oakland, CA
Click here to add this to my saved trials
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
A Randomized, Phase II Multicenter Trial Evaluating the Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)
Status: Enrolling
Updated:  1/13/2016
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)
A Randomized, Phase II Multicenter Trial Evaluating the Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)
Status: Enrolling
Updated: 1/13/2016
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
A Phase II Randomized, Open Label Trial Comparing the Effects of Intermittent Vismodegib Versus PDT on the Maintenance of Benefit Following 7 Months of Continuous Vismodegib Treatment in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  1/13/2016
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
A Phase II Randomized, Open Label Trial Comparing the Effects of Intermittent Vismodegib Versus PDT on the Maintenance of Benefit Following 7 Months of Continuous Vismodegib Treatment in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 1/13/2016
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
A Phase II Randomized, Open Label Trial Comparing the Effects of Intermittent Vismodegib Versus PDT on the Maintenance of Benefit Following 7 Months of Continuous Vismodegib Treatment in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  1/13/2016
Children's Hospital Oakland Research Institiute
mi
from
Oakland, CA
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
A Phase II Randomized, Open Label Trial Comparing the Effects of Intermittent Vismodegib Versus PDT on the Maintenance of Benefit Following 7 Months of Continuous Vismodegib Treatment in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 1/13/2016
Children's Hospital Oakland Research Institiute
mi
from
Oakland, CA
Click here to add this to my saved trials
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
A Phase II Randomized, Open Label Trial Comparing the Effects of Intermittent Vismodegib Versus PDT on the Maintenance of Benefit Following 7 Months of Continuous Vismodegib Treatment in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated:  1/13/2016
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
A Phase II Randomized, Open Label Trial Comparing the Effects of Intermittent Vismodegib Versus PDT on the Maintenance of Benefit Following 7 Months of Continuous Vismodegib Treatment in Patients With Multiple Basal Cell Carcinomas
Status: Enrolling
Updated: 1/13/2016
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
University of California, Irvine - Dermatology Research
mi
from
Irvine, CA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
University of California, Irvine - Dermatology Research
mi
from
Irvine, CA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Plastic Surgery and Laser Institute of San Diego
mi
from
La Jolla, CA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Plastic Surgery and Laser Institute of San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Scripps Memorial-Ximed Medical Center
mi
from
La Jolla, CA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Scripps Memorial-Ximed Medical Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Advanced Cosmetic Surgery Clinic of Walnut Creek
mi
from
Walnut Creek, CA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Advanced Cosmetic Surgery Clinic of Walnut Creek
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Anthony DeMeo, MD
mi
from
Walnut Creek, CA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Anthony DeMeo, MD
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Charles Hanson MD
mi
from
Walnut Creek, CA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Charles Hanson MD
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
PIH Health Plastic Surgery and Aesthetic Medicine
mi
from
Whittier, CA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
PIH Health Plastic Surgery and Aesthetic Medicine
mi
from
Whittier, CA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
PIH health
mi
from
Whittier, CA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
PIH health
mi
from
Whittier, CA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Sanctuary Mediacal Center
mi
from
Boca Raton, FL
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Sanctuary Mediacal Center
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Stephan Baker, MD PA
mi
from
Coral Gables, FL
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Stephan Baker, MD PA
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Altus Research
mi
from
Lake Worth, FL
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Altus Research
mi
from
Lake Worth, FL
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Bayside Ambulatory Center
mi
from
Miami, FL
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Bayside Ambulatory Center
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
University of South Florida
mi
from
Tampa, FL
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Atlanta APC Plastic Surgery
mi
from
Atlanta, GA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Atlanta APC Plastic Surgery
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Kavali Plastic Surgery and Skin Renewal Center
mi
from
Atlanta, GA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Kavali Plastic Surgery and Skin Renewal Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Perimeter Outpatient Surgery Center
mi
from
Atlanta, GA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Perimeter Outpatient Surgery Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Advanced Medical Resarch ,Inc
mi
from
Atlanta, GA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Advanced Medical Resarch ,Inc
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Atlanta APC Plastic Surgery
mi
from
Conyers, GA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Atlanta APC Plastic Surgery
mi
from
Conyers, GA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Spivey Station Surgery Center
mi
from
Jonesboro, GA
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Spivey Station Surgery Center
mi
from
Jonesboro, GA
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Northwestern University Diagnostic Testing Center
mi
from
Chicago, IL
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Northwestern University Diagnostic Testing Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Northwestern University,Division of Plastic Surgery
mi
from
Chicago, IL
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Northwestern University,Division of Plastic Surgery
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Body Aesthetic Research Center
mi
from
Saint Louis, MO
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Body Aesthetic Research Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Mercy Clinic Heart and Vascular
mi
from
St. Louis, MO
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Mercy Clinic Heart and Vascular
mi
from
St. Louis, MO
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Long Island Plastic Surgical Group
mi
from
Garden City, NY
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Long Island Plastic Surgical Group
mi
from
Garden City, NY
Click here to add this to my saved trials
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated:  1/19/2016
Long Island Plastic Surgical Group, PC
mi
from
Manhasset, NY
Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery
A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring
Status: Enrolling
Updated: 1/19/2016
Long Island Plastic Surgical Group, PC
mi
from
Manhasset, NY
Click here to add this to my saved trials